Publication: Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms
Program
KU-Authors
KU Authors
Co-Authors
Kaymaz-Tahra, Sema
Tsechelidis, Ozun Bayindir
Ince, Burak
Ozdemir-Isik, Ozlem
Kutu, Muhammet Emin
Karakas, Ozlem
Demirci-Yildirim, Tuba
Ademoglu, Zeliha
Ediboglu, Elif
Uludogan, Burcu Ceren
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to assess the characteristics of TAK patients needed biologic treatment during follow-up in daily practice.
Source
Publisher
Wiley
Subject
Rheumatology
Citation
Has Part
Source
ARTHRITIS and RHEUMATOLOGY
Book Series Title
Edition
DOI
item.page.datauri
Link
Rights
N/A